TheEdgeResearch
Home / Stocks / BFRI

Biofrontera Inc. (BFRI)

NASDAQ Healthcare Medical - Pharmaceuticals
$0.53 ▼ -7.02%
Market Cap
$7.9M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.96
52-Wk Range
0.53-1.66
CEO
Hermann Lübbert
Country
US
Currency
USD

Biofrontera Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Woburn, MA, US. The stock last traded at $0.53, down 7.02% on the session, giving a market capitalisation of $7.9M. On trailing twelve-month figures it carries a trailing P/E of -1.33, a net margin of -12.7%. Its beta of 0.96 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.33
Price / Sales
0.16
Price / Book
-33.33
EV / EBITDA
-2.28
Gross margin
84.6%
Operating margin
-9.5%
Net margin
-12.7%
Return on equity
—
Debt / equity
-31.00
Current ratio
0.78
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
89
IPO date
2021-10-29
Headquarters
Woburn, MA, US
About Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Comparable companies

Biofrontera Inc. is most often compared with the following Healthcare names:

AYTUCOCPDWTXEVGNGELSIMNNPRPHSBFMSNSETRIB
More research on BFRI
BFRI technical analysis BFRI TheEdge Score Compare against peers
Open full interactive analysis & DCF →